Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial Endpoints NewsRoche unveils data behind BTK inhibitor’s phase 3 multiple sclerosis win in Ocrevus trial Fierce BiotechRO: Fenebrutinib matched ocrelizumab in slowing PPMS progression, with strong upper limb benefits TradingViewRoche’s multiple sclerosis drug fenebrutinib meets goal in late-stage trial ET PharmaACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial Multiple Sclerosis News Today
